The human epidermal growth factor 2 (HER2)–overexpressing (HER2-positive [HER2+])
gastric (GC) and gastroesophageal junction adenocarcinomas (GEJC) are felt to represent a …

Objective (s): Expression of HER2 in gastric carcinoma has direct prognostic and therapeutic
implications in patient management. The aim of this study is to determine whether a …

Purpose This study evaluated the usefulness of semiquantitative and volumetric PET
parameters for predicting prognosis in patients with advanced gastric cancer (AGC) …

18F-FDG PET has been widely used in the management of malignant tumors. In gastric
cancer, the status of human epidermal growth factor receptor 2 (HER2) predicts the …

Background We aimed to find the clinical value of metastatic tumor burden evaluated with
F18-FDG PET/CT in gastric cancer patients, considering the human epidermal growth factor …

Objectives: The aim of this study was to evaluate 18 F-fluoro-2-deoxy-glucose (FDG) uptake
patterns in primary tumors and metastatic lesions, and also to assess the diagnostic …

Objectives: Human epidermal growth factor receptor-2 (HER-2) is a protooncogene encoded
by ERBB2 on chromosome 17. 18 Fluoridefluorodeoxyglucose positron emission …

The present study aimed to investigate the prognostic value of intra-tumor metabolic
heterogeneity on 2-[18F] Fluoro-2-deoxy-d-glucose (18 F-FDG) positron emission …

Purpose Few studies have evaluated metabolic activity by 18 F-FDG PET as a prognostic
factor in advanced gastric cancer (AGC). We investigated its prognostic role in metastatic …

Objective The aim of this study was to evaluate PET/FDG metabolic parameters in locally
advanced GEJC and correlate it with molecular pathological profiles. Methods We …